Therefore, the addition of radiotherapy (RT) could further enhance the antitumor efficacy of the dual-combination therapeutic strategy of anti-PD1/PDL1 plus anti-angiogenesis, in part because of a direct effect on the tumor stroma, including immune cells and blood vessels.[5] On the one hand, RT can reactivate immune response in the tumor microenvironment.[6] On the other hand, angiogenesis can augment the efficacy of RT by normalizing tumor vessels and forming an immunology-friendly tumor microenvironment. This evidence concerns the gene PDCD1 and neoplasm.